Clinical Trial Update: Test-retest Evaluation of [18F]F-AraG PET [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the test-retest reliability of the [18F]F-AraG PET tracer in non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• [18F]F-AraG

Snippet

Sponsor: CellSight Technologies, Inc. | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING